Key Takeaways
- Mouse models are a critical tool in mesothelioma research — mice share similar genetic panels with humans, and mouse-model research has increased mesothelioma treatment response rates from less than 10% to approximately 50% over the past three decades.
- Dr. Daniel Murphy has identified a genetic combination that results in mice developing mesothelioma 100% of the time after asbestos exposure — allowing researchers to study the disease from its earliest pre-cancerous stages.
- This is groundbreaking because it lets scientists observe “pre-mesothelioma” — the stage between asbestos exposure and cancer onset — which has never been reliably studied before. Understanding how inflammation transitions into cancer could lead to early detection and even prevention.
- Mouse models have traditionally been used to test treatment safety and efficacy before human trials. Dr. Murphy’s work expands their use into diagnostics and prevention — shifting the goal from treating mesothelioma to stopping it before it develops.
- The long-term goal is to develop a screening process for asbestos-exposed individuals that can identify and potentially reverse the carcinogenic process before mesothelioma forms.
What is a Mouse Model? Are they Relevant?
Mice are useful models for human physiology, as they are mammals that share similar genetic panels to humans. This means that drugs, surgeries, and modifications to bodily needs will (for the most part) be accurately reflected in mouse models. Usually, mouse models are utilized prior to clinical trials to ensure the safety and relative efficacy of new therapeutic techniques before they’re administered to people.
In mesothelioma research, mouse models account for an increase in treatment response rate of less than 10% to about 50% in the last three decades. This means that mice have increased the efficacy of treatments (and have laid the groundwork for new treatments) by over 40%. Importantly, mouse models usually aren’t predictive, meaning they can’t tell us more about a disease than we already know. This makes using mouse models difficult in the context of exploration or diagnostics, but doesn’t really affect their utility for treatment models.
Mouse Model Diagnostics?
As we’ve established, mouse models usually aren’t predictive. However, in the context of mesothelioma, researchers have found that early presentations of mesothelioma look (and act) similar in humans and mice. The phase right before mesothelioma onset and the beginning stages of the cancer present like inflammation, which makes sense: ingested asbestos causes chronic inflammation of the linings of body cavities. This inflammation, scientists hypothesize, is what causes mesothelioma tumors to develop in the first place. Despite knowing this, it’s difficult to distinguish between inflammation that gives rise to mesothelioma and other kinds of inflammation, like pneumonia or lung cancer.
Up until this point, biopsies—samples of living tissue—have been the only way to certify a mesothelioma diagnosis. Although biopsies are the standard for credible diagnosis, still some cases of mesothelioma are misdiagnosed. If a biopsy only sweeps an area of inflammation, or a part of a tumor that is different than what’s expected of mesothelioma cells, then there’s a real risk of receiving an inaccurate diagnosis. Inaccurate diagnoses mean that mesothelioma isn’t treated promptly, which can decrease overall survival and compromise the patient’s quality of life.
Mesothelioma Diagnosis Using Mouse Models
Dr. Daniel Murphy is working to address the diagnostic model of mesothelioma via mouse research. Researching the oncogenesis of mesothelioma is just as important as researching treatment options: if we can understand how to track, interfere with, or reverse the effects of chronic asbestos-induced inflammation, then treatment becomes secondary. Dr. Murphy established a combination of genes that, when a mouse is introduced to asbestos, it’ll develop an analog of mesothelioma in 100% of trials. This has several implications: for one, scientists can roughly identify which genes contribute to mesothelioma development. Additionally—and most importantly—scientists can use these mice to study how “pre-mesothelioma” looks, behaves, and manifests as. These findings can inform new screening measures for people that have been exposed to asbestos but haven’t developed mesothelioma. Additionally, these findings will help establish the exact mechanisms by which inflammation leads to mesothelioma tumors.
Dr. Murphy is aiming to use his findings—which are still in the experimental phase—in order to develop a screening process for identifying (and eventually reversing) the carcinogenic process. In this way, the mouse model could revolutionize the ways in which we think about a.) the genetic factors that culminate in a mesothelioma diagnosis; b.) stopping mesothelioma before it develops; and c.) how treatment models might eventually become prevention models.
If you or a loved one has been diagnosed with mesothelioma or another asbestos-related disease, we are here to help. Our website offers useful information regarding types of asbestos-related diseases, hospitals to receive treatment in Pennsylvania, a variety of different treatment options, and more. For more information or for legal help, please call us at (800) 505-6000 or simply fill out our contact form.
Frequently Asked Questions
What is a mouse model and why is it used in mesothelioma research?
A mouse model uses mice as stand-ins for human biology because they are mammals with genetic panels similar to humans. Drugs, surgical techniques, and other treatments can be tested in mice before being administered to people, ensuring safety and establishing baseline efficacy. In mesothelioma research specifically, mouse models have been responsible for increasing treatment response rates from less than 10% to approximately 50% over the past three decades — a significant advancement driven by animal research.
What did Dr. Daniel Murphy discover?
Dr. Murphy identified a specific combination of genes that, when present in mice exposed to asbestos, results in mesothelioma development 100% of the time. This is a critical finding because it gives researchers a reliable, repeatable model for studying the entire disease progression — from initial asbestos exposure through chronic inflammation to full cancer onset. It also allows scientists to identify which specific genes contribute to mesothelioma development.
Why is studying “pre-mesothelioma” important?
One of the biggest challenges in mesothelioma is that the disease is nearly impossible to detect during its 20- to 50-year latency period — by the time symptoms appear and a diagnosis is made, the cancer is often already advanced. Dr. Murphy’s mouse model allows researchers to observe what happens between asbestos exposure and cancer onset — the pre-mesothelioma phase. Understanding how chronic inflammation transitions into cancer could lead to screening tools that detect the disease before tumors form, and potentially even interventions that stop the process entirely.
Could this research lead to mesothelioma prevention?
Potentially, yes. Dr. Murphy’s long-term goal is to use these findings to develop a screening process for people who have been exposed to asbestos but haven’t yet developed mesothelioma. If researchers can identify the exact mechanisms by which chronic inflammation leads to cancerous tumors, it may be possible to intervene during the latency period — turning what is currently a treatment problem into a prevention problem. This would represent a fundamental shift in mesothelioma care: from treating cancer after it develops to stopping it before it starts.
How does this connect to what we already know about mesothelioma genetics?
Dr. Murphy’s work builds on existing knowledge about genetic factors in mesothelioma. Research has already identified BAP1 as the gene most commonly mutated in mesothelioma (60–70% of cases), epigenetic changes that alter gene expression without changing DNA, and the EMT process by which epithelial cells become cancerous and migratory. The mouse model adds a new dimension: by identifying the specific genetic combination that guarantees mesothelioma development after asbestos exposure, it helps researchers understand which genetic factors are necessary versus incidental for the disease to develop.
Are mouse model findings directly applicable to humans?
Mouse models provide valuable insights but are not a direct one-to-one translation to human biology. Treatments and findings that work in mice must still be validated through human clinical trials before they can be implemented. However, the early stages of mesothelioma — particularly the inflammation-to-cancer progression — appear to present similarly in mice and humans, making the mouse model a useful tool for understanding disease mechanisms and identifying potential screening and prevention strategies.
What should I do if I was exposed to asbestos but haven’t been diagnosed with mesothelioma?
If you have a history of asbestos exposure but have not been diagnosed with mesothelioma, inform your doctor about your exposure history and ask about monitoring options — including regular imaging and blood tests for biomarkers like mesothelin and calretinin. While the screening tools from Dr. Murphy’s research are not yet available for clinical use, proactive monitoring with existing tools can still lead to earlier detection. If you or a loved one has been diagnosed with mesothelioma, call (800) 505-6000 or fill out our contact form for a free consultation.
